Alba Valiente-Pallejà
Research Subjects
Alba Valiente-Pallejà has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Lourdes Martorell
Hospital Universitari Institut Pere Mata (HUIPM), Institut d'Investigació Sanitària Pere Virgili (IISPV-CERCA), Universitat Rovira i Virgili (URV), CIBERSAM-ISCIII
5 shared publications - Elisabet Vilella
Hospital Universitari Institut Pere Mata (HUIPM), Institute de Recerca Biomédica Catalunya Sud (IRB-CatSud) previously IISPV-CERCA, Universitat Rovira i Virgili (URV), Reus, Spain
4 shared publications - Bengisu Kevser Bulduk
Hospital Universitari Institut Pere Mata (HUIPM) Reus Catalonia Spain
3 shared publications - Gerard Muntané
Institut de Recerca Biomèdica Catalunya Sud, Reus, Spain
3 shared publications - Juan Tortajada Valero
Hospital Universitari Institut Pere Mata (HUIPM) Reus Catalonia Spain
3 shared publications - Helena Torrell
Eurecat, Centre Tecnològic de Catalunya, Center for Omic Sciences (COS), Joint Unit Universitat Rovira i Virgili-EURECAT, Unique Scientific and Technical Infrastructures (ICTS), 43204 Reus, Spain
2 shared publications
Latest Publications
- Open Access
- 1 June 2026
- Published by Wiley in General Psychiatry
- Vol. 39 (3) , e70023
Clinical outcomes of mitochondrial‐enhancing nutraceutical supplementation in psychiatric disorders: A systematic review
Background: Nutraceutical supplementation targeting mitochondrial function has been proposed as a beneficial therapeutic strategy to improve physical and mental health in psychiatric patients. Aims: To summarise the results of studies evaluating nutraceutical supplementation targeting mitochondrial function in patients with psychiatric disorders. Methods: Following the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses guidelines, we searched PubMed, Embase and Scopus databases from 1 January 2007 to 30 April 2024. Reports were included if they evaluated outcomes of nutraceutical supplementation in patients with psychiatric disorders or related conditions. Additionally, we performed a risk‐of‐bias analysis of the studies compatible with the RoB2 tool. Results: Of the 2061 records identified, 122 studies met the inclusion criteria, evaluating vitamin D3, N‐acetylcysteine, acetyl‐L‐carnitine, coenzyme Q10, alpha‐lipoic acid, magnesium, vitamin B6, vitamin B7, folic acid, vitamin B12, vitamin E, vitamin A, vitamin C and vitamin B3. The most studied nutraceuticals were vitamin D3 (27.05%) and N‐acetylcysteine (15.6%). Among randomised controlled clinical trials (RCTs), vitamin D3 was the most extensively investigated and accounted for the highest number of trials reporting improvements in clinical outcomes, although findings were heterogeneous. Notably, 14.8% of the studies evaluated combinations of three or more nutraceuticals. Dietary supplements were extensively evaluated for autism spectrum disorder (28 studies), schizophrenia spectrum disorder (27 studies), major depressive disorder or related depressive symptoms (22 studies), attention‐deficit hyperactivity disorder (9 studies) and bipolar spectrum disorder (6 studies). A substantial proportion of studies were not RCTs but open‐label single‐arm trials or case reports. Significant heterogeneity was observed in the nutraceutical components used, treatment duration and the outcomes assessed. Overall, the risk of bias was high, and the methodological quality was generally low. Conclusions: Promising findings in nutraceutical studies for psychiatric disorders face challenges, including small sample sizes, short follow‐up periods and a lack of treatment standardisation. Future research requires robust RCTs with standardised protocols and validated biomarkers of efficacy.
- 1 June 2026
- Published by Wiley in General Psychiatry
- Vol. 39 (3) , e70023
Open AccessClinical outcomes of mitochondrial‐enhancing nutraceutical supplementation in psychiatric disorders: A systematic review
Background: Nutraceutical supplementation targeting mitochondrial function has been proposed as a beneficial therapeutic strategy to improve physical and mental health in psychiatric patients. Aims: To summarise the results of studies evaluating nutraceutical supplementation targeting mitochondrial function in patients with psychiatric disorders. Methods: Following the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses guidelines, we searched PubMed, Embase and Scopus databases from 1 January 2007 to 30 April 2024. Reports were included if they evaluated outcomes of nutraceutical supplementation in patients with psychiatric disorders or related conditions. Additionally, we performed a risk‐of‐bias analysis of the studies compatible with the RoB2 tool. Results: Of the 2061 records identified, 122 studies met the inclusion criteria, evaluating vitamin D3, N‐acetylcysteine, acetyl‐L‐carnitine, coenzyme Q10, alpha‐lipoic acid, magnesium, vitamin B6, vitamin B7, folic acid, vitamin B12, vitamin E, vitamin A, vitamin C and vitamin B3. The most studied nutraceuticals were vitamin D3 (27.05%) and N‐acetylcysteine (15.6%). Among randomised controlled clinical trials (RCTs), vitamin D3 was the most extensively investigated and accounted for the highest number of trials reporting improvements in clinical outcomes, although findings were heterogeneous. Notably, 14.8% of the studies evaluated combinations of three or more nutraceuticals. Dietary supplements were extensively evaluated for autism spectrum disorder (28 studies), schizophrenia spectrum disorder (27 studies), major depressive disorder or related depressive symptoms (22 studies), attention‐deficit hyperactivity disorder (9 studies) and bipolar spectrum disorder (6 studies). A substantial proportion of studies were not RCTs but open‐label single‐arm trials or case reports. Significant heterogeneity was observed in the nutraceutical components used, treatment duration and the outcomes assessed. Overall, the risk of bias was high, and the methodological quality was generally low. Conclusions: Promising findings in nutraceutical studies for psychiatric disorders face challenges, including small sample sizes, short follow‐up periods and a lack of treatment standardisation. Future research requires robust RCTs with standardised protocols and validated biomarkers of efficacy.
- 1 October 2021
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 51, e236-e237
TH79. MITOCHONDRIAL DNA ALTERATIONS IN THE POSTMORTEM BRAIN OF PSYCHIATRIC DISEASES: A SYSTEMATIC REVIEW
- 1 October 2021
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 51, e236-e237
TH79. MITOCHONDRIAL DNA ALTERATIONS IN THE POSTMORTEM BRAIN OF PSYCHIATRIC DISEASES: A SYSTEMATIC REVIEW
- 1 June 2020
- Published by Elsevier in Schizophrenia Research
- Vol. 220, 61-68
Increased blood lactate levels during exercise and mitochondrial DNA alterations converge on mitochondrial dysfunction in schizophrenia
- 1 June 2020
- Published by Elsevier in Schizophrenia Research
- Vol. 220, 61-68
Increased blood lactate levels during exercise and mitochondrial DNA alterations converge on mitochondrial dysfunction in schizophrenia
- 24 April 2020
- Published by Cambridge University Press (CUP) in Acta Neuropsychiatrica
- Vol. 32 (5) , 265-269
High frequency of clinical conditions commonly associated with mitochondrial disorders in schizophrenia
Objective: It has been hypothesised that neuropsychiatric symptoms, including psychosis, can be the result of a milder brain bioenergetic defect produced by mitochondrial dysfunction; however, mitochondrial dysfunction can be present in other organs or systems. The aim of the study was to investigate whether clinical conditions associated with mitochondrial disorders (CAMDs) were frequently present in schizophrenia.Methods: A previously used questionnaire regarding the CAMDs was administered to patients and controls in a direct interview with a trained psychiatrist. The frequencies of CAMDs in 164 patients with schizophrenia were compared to those in 156 age- and sex-matched controls.Results: Severe fatigue, seizures, constipation and diabetes were significantly more frequent in patients with schizophrenia than in control subjects and apparently not related to pharmacological treatment.Conclusion: The results of the present study suggest that multi-systemic mitochondrial dysfunction may be an underlying mechanism involved in schizophrenia.
- 24 April 2020
- Published by Cambridge University Press (CUP) in Acta Neuropsychiatrica
- Vol. 32 (5) , 265-269
High frequency of clinical conditions commonly associated with mitochondrial disorders in schizophrenia
Objective: It has been hypothesised that neuropsychiatric symptoms, including psychosis, can be the result of a milder brain bioenergetic defect produced by mitochondrial dysfunction; however, mitochondrial dysfunction can be present in other organs or systems. The aim of the study was to investigate whether clinical conditions associated with mitochondrial disorders (CAMDs) were frequently present in schizophrenia.Methods: A previously used questionnaire regarding the CAMDs was administered to patients and controls in a direct interview with a trained psychiatrist. The frequencies of CAMDs in 164 patients with schizophrenia were compared to those in 156 age- and sex-matched controls.Results: Severe fatigue, seizures, constipation and diabetes were significantly more frequent in patients with schizophrenia than in control subjects and apparently not related to pharmacological treatment.Conclusion: The results of the present study suggest that multi-systemic mitochondrial dysfunction may be an underlying mechanism involved in schizophrenia.